PLASOMA Ultimate Safety & Efficacy Study

Diabetic Foot Ulcer Clinical Trial

— PULSE  

Official title:

PLASOMA Ultimate Safety & Efficacy Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04828304
• Other study ID #: PULSE study
• Status: Active, not recruiting
• Phase: N/A
• Start date: May 26, 2021
• Est. completion date: December 2024

Study information

• Verified date: December 2023
• Source: Plasmacure
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the PULSE study are the followingL A.To perform post market clinical follow up (PMCF) on safety and efficacy: 1. Safety: To confirm transient short-terms side effects and verify long-term/outstanding risks. 2. Efficacy: To confirm the performance of PLASOMA, i.e. the beneficial effect on bacterial load. B. Determine the effect of PLASOMA on wound surface area. A secondary purpose is to examine the beneficial effects of PLASOMA on wound healing and to perform a health technology assessment (HTA). This clinical study will be an open label two-armed randomized controlled trial (RCT), performed at at least three sites (multi-center) in the Netherlands. The two arms are: 1. Control group: Standard wound care for 12 weeks or until healing, whichever occurs first; 2. Treatment group: Standard wound care + PLASOMA treatment for 12 weeks or until healing, whichever occurs first. The frequency of PLASOMA treatment will be determined by the treating (para)medical professional based on the number of visits they would schedule for the standard wound care at the study site. For all study subjects, the treatment frequency will be at least once per week (in order to have enough treatments for safety evaluation) and should not exceed once per day. Follow up (FU) will be performed at three timepoints for both arms: - FU1: 2 weeks after end treatment period - FU2: 12 weeks after end treatment period - FU3: 12 months after start treatment.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 101
• Est. completion date: December 2024
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

INCL1: have a slow-healing or non-healing ulcer consisting of, but not limited to:

• diabetic ulcers (Wagner-Meggitt classification system/ University of Texas classification system: grades 1-3)
• venous ulcers
• pressure ulcers (international NPUAP/EPUAP classification system: categories/stages II-IV)
• burn wounds (second and third degree)
• skin grafts and flaps
• infected post-surgical ulcers. Standard wound care has not resulted in sufficient healing after at least two weeks (including first line care) (Ref 25, Ref 26). Note: There is no upper limit for the duration that the wound exists. In case a subject has multiple wounds that meet the in- and exclusion criteria, the wound with the longest duration will be chosen for the study. INCL2: have a wound with a minimum wound surface area of 0.5 cm2 and a maximum diameter of 4.5 cm (~16 cm2 wound surface area for circular wounds). INCL3: have a minimum age of 18 years old. INCL4: for home care treatments only: have a grounded wall socket available for connection of PLASOMA. Exclusion criteria:

EXCL1: the subject has one or more of the following contraindications for PLASOMA:

• the wound is very exudative, i.e. wounds in which moisture is visible again within a few minutes after patting dry.
• any implanted active electronic device, such as a pacemaker, is present.
• an electronic medical device is attached to the body, including electronic life support equipment, hearing aids, glucose sensors and insulin pumps. If the sole purpose of the medical device is monitoring, the subject is not excluded, but it should be noted that use of PLASOMA together with such devices has not been tested and may lead to erroneous operation of the attached device during PLASOMA treatment.
• Note: no exclusion if electronic medical device will be detached during PLASOMA treatment.
• a metal implant (including a stent) is present in the treatment area, i.e. the area between pad and electrode.
• a conductive connection from outside to inside the body at or near the heart is present, e.g. a catheter with electrolyte fluid.
• the subject has epilepsy
• the subject is pregnant
• the to-be-treated wound is located on the torso above the navel EXCL2: the subject has any known malignant wound degeneration. EXCL3: the subject receives treatment with immunosuppressive agents or oral corticosteroids; no exclusion if subject has received a stable dose for at least 2 months and the oral corticosteroid dose does not exceed 7.5 mg/day prednisone or equivalent. EXCL4: the subject is receiving or likely to receive advanced wound therapies - such as negative pressure therapy, hyperbaric oxygen therapy, biologicals (e.g. skin substitutes, growth factors), electrophysical therapy - until FU1 for the to be-treated wound. Advanced wound dressings are not excluded. EXCL5: the subject participates in another study which is likely to compromise the outcome of the PULSE study or the feasibility of the subject fulfilling the PULSE study. EXCL6: the subject is unable to provide consent.

Related Conditions & MeSH terms

• Burn Wound
• Diabetic Foot
• Diabetic Foot Ulcer
• Foot Ulcer
• Infected Surgical Wound
• Leg Ulcer
• Pressure Ulcer
• Skin Flap
• Skin Graft
• Surgical Wound
• Surgical Wound Infection
• Ulcer
• Varicose Ulcer
• Venous Leg Ulcer
• Wounds and Injuries

Intervention

Device:
• PLASOMA
Treatment with cold plasma device

Locations

Country	Name	City	State
Netherlands	Groene Hart Ziekenhuis	Gouda
Netherlands	Alrijne Ziekenhuis	Leiderdorp
Netherlands	Sint Antonius Ziekenhuis	Nieuwegein
Netherlands	radboud Universitair Medisch Centrum	Nijmegen
Netherlands	Expertisecentrum Wondzorg (EcW)	Oosterhout
Netherlands	Maxima Medisch Centrum (MMC)	Veldhoven

Sponsors (3)

Lead Sponsor	Collaborator
Plasmacure	Diabetes Fonds, Pathology and Medical Microbiology

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety PLASOMA - device related SAEs	device related SAEs	12 months
Primary	Efficacy PLASOMA - bacterial load reduction - Staphylococcus aureus	Reduction in number of S. aureus colonies, using wound swab and quantitative analysis	once at week 1 (wound swab directly before and after first PLASOMA treatment)
Primary	Efficacy PLASOMA - wound surface area reduction	Wound surface area reduction	12 weeks
Secondary	Safety PLASOMA - all AEs	Safety reporting	12 months
Secondary	Safety PLASOMA - wound appearance	wound appearance	24 weeks
Secondary	Efficacy PLASOMA - Bacterial load reduction	Bacterial load reduction (total load and Pseudomonas aeruginosa), using wound swab and semi-quantitative analysis	once at week 1 (wound swab directly before and after first PLASOMA treatment)
Secondary	Efficacy PLASOMA- wound healing	Wound healing - wound surface area reduction - wound volume reduction - time to healing	12 weeks
Secondary	Efficacy PLASOMA - Quality of Life	Quality of Life, using RAND-36 questionnaire	14 weeks
Secondary	Efficacy PLASOMA - Quality of Life	Quality of Life, using Wound-QoL questionnaire	14 weeks
Secondary	Efficacy PLASOMA - Ulcer recurrence	Ulcer recurrence	12 months
Secondary	Efficacy PLASOMA - wound infection	wound infection (clinical classification)	12 weeks
Secondary	Efficacy PLASOMA - wound pain	wound pain (0-10 numerical rating scale)	12 weeks
Secondary	Health Technology Assessment PLASOMA	resource usage PLASOMA	12 weeks
Secondary	Patient acceptability	Patient acceptability (subjects will be asked if they are happy with the PLASOMA treatment)	12 weeks